Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2024-2032
세계 단클론항체 시장 규모는 2023년 2,217억 달러에 달했습니다. 향후 IMARC Group은 2032년까지 시장 규모가 3,926억 달러에 달해 2024-2032년 사이 6.4%의 연평균 성장률(CAGR)을 기록할 것으로 예상하고 있습니다.
단클론항체(mAbs)는 원치 않는 세포에 대한 면역체계의 공격을 강화, 수정, 복구, 모방할 수 있는 대체 항체로 사용되는 실험실에서 생산되는 단백질입니다. 면역체계를 강화하여 암세포를 탐지하고 표적화하여 파괴하는 데 활용됩니다. 또한, 암세포와 세포 증식을 촉진하는 단백질과의 결합을 억제하는 데에도 사용됩니다. 또한, 면역계 세포가 암세포에 대해 효율적으로 작용할 수 있도록 단백질 형성을 억제합니다. 이 외에도 mAbs는 방사선 치료를 암세포에 직접 전달하여 건강한 세포에 대한 방사선의 영향을 최소화합니다.
단클론항체 시장 동향:
현재 암, 심장병, 뇌졸중, 당뇨병, 관절염 등 만성질환의 유병률 증가는 시장을 주도하는 중요한 요인 중 하나입니다. 또한, 주요 제조업체들은 알츠하이머병, 헌팅턴병, 파킨슨병, 레비소체병과 같은 신경 퇴행성 질환의 치료를 위해 강화된 mAb 약물을 도입하기 위해 연구 개발(R&D) 활동에 광범위하게 투자하고 있습니다. 또한, 고객 기반을 확대하기 위해 다양한 마케팅 전략에 집중하고 있으며, 이는 시장 성장에 기여하고 있습니다. 또한, 암세포, 면역 억제, 면역 조절 분자 등 다양한 항원을 치료하기 위한 인간화 mAb에 대한 수요 증가는 업계 투자자들에게 유리한 성장 기회를 제공하고 있습니다. 이와는 별도로, 암 치료를 위한 비용 효율적인 바이오시밀러 mAbs에 대한 수요가 전 세계적으로 증가하고 있습니다. 이는 급성장하는 의료 산업과 함께 시장 성장을 촉진하고 있습니다. 또한 차세대 염기서열 분석과 같은 다양한 유전자 플랫폼의 기술 발전은 시장 전망에 긍정적인 영향을 미치고 있습니다. 또한, 전 세계적으로 mAb 생산에 있어 첨단 유전공학 기술의 채택이 증가하고 있습니다. 이는 mAb 치료의 이점에 대한 대중의 인식이 높아짐에 따라 시장 성장을 촉진하고 있습니다.
본 보고서에서 다루는 주요 질문들
- 2023년 세계 단클론항체 시장 규모는?
- 2024-2032년 단클론항체 세계 시장 성장률 전망은?
- 단클론항체 세계 시장을 주도하는 주요 요인은 무엇인가?
- COVID-19가 세계 단클론항체 시장에 미친 영향은?
- 생산 방법별 단클론항체 세계 시장 현황은?
- 세계 시장에서 단클론항체의 공급원별 분류는?
- 적응증별 세계 단클론항체 시장 현황은?
- 단클론항체의 최종 용도별 세계 시장 현황은?
- 단클론항체 세계 시장의 주요 지역은?
- 단클론항체 세계 시장 주요 진출 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 단클론항체 세계 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 생산 방법별
제7장 시장 내역 : 공급원별
제8장 시장 내역 : 적응증별
제9장 시장 내역 : 최종 용도별
제10장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제14장 가격 분석
제15장 경쟁 상황
- 시장 구조
- 주요 기업
- 주요 기업 개요
- AbbVie Inc.
- Amgen Inc.
- Biogen Inc.
- F. Hoffmann-La Roche AG
- GSK plc
- Johnson & Johnson
- Merck KGaA
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi S.A.
- Thermo Fisher Scientific Inc.
ksm
The global monoclonal antibodies market size reached US$ 221.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 392.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.4% during 2024-2032.
Monoclonal antibodies (mAbs) are laboratory-produced proteins used to serve as substitute antibodies that can enhance, modify, restore, and mimic the attack of the immune system on unwanted cells. They are utilized for detecting and targetting cancer cells for destruction by enhancing the immune system. They are also employed to block the connection between a cancer cell and proteins that promote cell growth. In addition, they prevent the formation of proteins for enabling immune system cells to work efficiently against cancer cells. Besides this, mAbs transport the radiation treatment directly to cancer cells and minimize the effect of radiation on healthy cells
Monoclonal Antibodies Market Trends:
At present, the growing prevalence of chronic diseases, such as cancer, heart disease, stroke, diabetes, and arthritis, represents one of the key factors driving the market. Besides this, leading manufacturers are extensively investing in research and development (R&D) activities to introduce enhanced mAb drugs for treating neurodegenerative diseases, such as Alzheimer's, Huntington's, Parkinson's, and Lewy body diseases. They are also focusing on various marketing strategies to expand their customer base, which is contributing to the growth of the market. In addition, the increasing demand for humanized mAbs to treat various antigens, such as cancer cells, immunosuppression, and immunomodulatory molecules, are offering lucrative growth opportunities to industry investors. Apart from this, there is a rise in the demand for cost-efficient biosimilar mAbs to treat cancer across the globe. This, along with the burgeoning healthcare industry, is propelling the growth of the market. Moreover, technological advancements in various genetic platforms, such as next-generation sequencing, is offering a positive market outlook. Additionally, there is an increase in the employment of advanced genetic engineering technology in mAbs production around the world. This, coupled with the rising awareness among the masses about the benefits of mAb therapy, is bolstering the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global monoclonal antibodies market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on production method, source, indication and end use.
Breakup by Production Method:
In Vivo
In Vitro
Breakup by Source:
Murine
Chimeric
Humanized
Human
Breakup by Indication:
Cancer
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Others
Breakup by End Use:
Hospitals
Research Institutes
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., Biogen Inc., F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report
- 1. What was the size of the global monoclonal antibodies market in 2023?
- 2. What is the expected growth rate of the global monoclonal antibodies market during 2024-2032?
- 3. What are the key factors driving the global monoclonal antibodies market?
- 4. What has been the impact of COVID-19 on the global monoclonal antibodies market?
- 5. What is the breakup of the global monoclonal antibodies market based on the production method?
- 6. What is the breakup of the global monoclonal antibodies market based on the source?
- 7. What is the breakup of the global monoclonal antibodies market based on the indication?
- 8. What is the breakup of the global monoclonal antibodies market based on the end use?
- 9. What are the key regions in the global monoclonal antibodies market?
- 10. Who are the key players/companies in the global monoclonal antibodies market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Monoclonal Antibodies Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Production Method
- 6.1 In Vivo
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 In Vitro
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Source
- 7.1 Murine
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Chimeric
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Humanized
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Human
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Indication
- 8.1 Cancer
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Autoimmune Diseases
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Inflammatory Diseases
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Infectious Diseases
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by End Use
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Research Institutes
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 AbbVie Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Amgen Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Biogen Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 F. Hoffmann-La Roche AG
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.5 GSK plc
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Johnson & Johnson
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Merck KGaA
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Novartis AG
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Novo Nordisk A/S
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Pfizer Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Sanofi S.A.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Thermo Fisher Scientific Inc.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
